Correvio Pharma has resubmitted a New Drug Application (NDA) to the US FDA seeking approval for Brinavess (vernakalant hydrochloride, IV), its antiarrhythmic drug for the rapid conversion of adult patients with recent onset atrial fibrillation (AF).
Tesaro has submitted a supplemental New Drug Application (sNDA) to the FDA for Zejula (niraparib). The application was granted priority review and has an action date of 24 October 2019.
Article written by Maria Dalby. Interview by Hannah Chatfield. Among the clinical studies that reported results at the EHA congress 2019 was part 1 of the CASSIOPEIA study…. read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Another study with significant practice implications is the COLUMBA study, presented by Professor Maria-Victoria Mateos (University Hospital of Salamanca, Spain). This… read more.
Article written by Maria Dalby. Interview by Hannah Chatfield. Oral selective BCL-2 inhibitor venetoclax has demonstrated encouraging clinical efficacy against MM. As monotherapy, venetoclax has shown to be… read more.
Professor Kwee Yong (London, UK) details the results from the Tourmaline-MM3 study
Autologous stem cell transplantation (ASCT) remains the standard of care option for those patients with newly-diagnosed multiple myeloma (MM) who are eligible for and able to tolerate… read more.
Professor Julie Vose (Nebraska, USA) updates us on the current status of BCMA CAR T-cell therapy.
Professor Sagar Lonial (Atlanta, USA) opened the UKMF by discussing the latest evidence in the management of myeloma, with comment from session chair Professor Gordon Cook (Leeds, UK).
Professor Graham Jackson (Newcastle, UK) gives an overview of his presentation on real world management of myeloma patients in the UK, with comments from Professor Sagar Lonial (Atlanta, USA). Professor Jackson… read more.
Professor Gordon Cook (Leeds, UK), Professor Guy Pratt (Birmingham, UK) and Professor Graham Jackson (Newcastle, UK) discuss the need for maintenance in the up-front setting for UK patients and the new data on… read more.
Dr Chris Fox (Nottingham, UK) highlights another presentation from Lymphoma SIG around the opportunities for genomic-driven change in lymphoma.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
